🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Consumer Discretionary Sector SEC Filings — May 14, 2026

Across 50 filings from May 14, 2026, primarily Q1 2026 results and 13F-HR holdings, the S&P 500 Consumer Discretionary stream reveals mixed performance with standout revenue accelerations in niche consumer-adjacent plays like Lifeway Foods (+37% YoY sales) and Newton Golf (operational expansions) amid broader sector challenges; however, energy-tied names like New Fortress Energy saw -52% YoY revenue collapses. Period-over-period trends highlight revenue growth in 7/15 operational filings averaging +85% YoY (outliers Forgent Power +103%, Scientist Home +321%), but margin pressures and capex surges led to net losses in 9/15 cases, with cash burns widening (e.g., WhiteFiber -33.8% QoQ cash). Institutional 13F-HRs (20+ filings) show heavy tech/consumer exposure (e.g., Nan Shan Life's $172M Alphabet, Swiss Life's massive Apple/Amazon), signaling conviction in discretionary leaders despite no direct insider buys noted. Forward-looking catalysts include raised guidances (Forgent FY2026 rev $1.35-1.39B, Hyperion DeFi gross profit $5-7M) and events like FREIT's Fall 2026 liquidation vote. Capital allocation leans toward capex/reinvestment (Lifeway $11M, Fermi $441M) over dividends/buybacks, with debt raises common (Wayfair $400M notes). Portfolio-level theme: Resilient growth pockets in food/golf/power contrast retail/energy weakness, favoring selective longs on guidance beats.

14 high priority 36 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — May 14, 2026

Across 50 filings in the USA S&P 500 Healthcare intelligence stream (despite cross-sector inclusions), Q1 2026 results from 10+ companies reveal robust revenue growth averaging +150% YoY in growth-oriented firms like Lifeway (+37%), Scientist Home (+321%), and UMeWorld (+85,000%), but persistent margin compression (-1,200bps avg in 5/8 cases) and opex explosions (+500% avg) drove wider net losses in 7/10, with cash burn accelerating and positions declining QoQ in 8/10 (e.g., Cellectar -37%, Senti -46%). Healthcare standouts include bullish biotech catalysts: Cellectar’s 61.8% major response rate in WM Phase 2b (iopofosine I 131), Editas’ 90% LDL-C reduction in NHP preclinical, and Senti Bio’s 70% YoY net loss reduction plus FDA pivotal trial nod. Institutional 13Fs (25/50 filings) signal conviction in healthcare via top holdings like McKesson (Seaview #1), AbbVie (multiple incl. Weaver, HRT, MFS), and biotechs Mineralys/Phathom (Catalys 93% portfolio). Capital allocation leans growth/reinvestment (Lifeway $11M capex, Cellectar $140M financing, Sixth Street $300M notes), with deal closes (HPE $987M) and backlogs (New Fortress $10B thru 2030) providing visibility. Portfolio implications: overweight biotech catalysts for alpha, underweight high-burn small caps amid liquidity risks; monitor ASCO June 1 and H1 2026 events.

11 high priority 39 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — May 14, 2026

Across 11 DEF 14A proxy statements filed around May 14, 2026, dominant themes include director elections (9/11 filings), advisory votes on executive compensation (6/11), auditor ratifications (7/11), and equity incentive plan expansions (2/11), signaling standard proxy season activities amid governance focus. EDAP TMS SA stands out with robust YoY HIFU revenue growth to record levels and new product launches, contrasting neutral/mixed sentiments elsewhere; no widespread period-over-period financial trends evident beyond EDAP's positive revenue and Signet's multi-year pay-vs-performance disclosures spanning FY2022-2026. High materiality events include Origin Materials' liquidation plan (10/10) and Mountain Lake's merger risks (9/10), implying bearish portfolio pressure in materials/SPAC segments. Neutral sentiment prevails (6/11), with mixed (1/11) and negative (2/11) outliers highlighting governance risks like Myomo's declassification proposal. Capital allocation leans toward equity incentives for talent retention, with no dividend/buyback mentions; upcoming June 2026 meetings form a dense catalyst calendar for votes on comp and plans.

11 high priority 11 total filings
· daily

US IPO Pipeline SEC S-1 Filings — May 14, 2026

The IPO Pipeline stream shows a surge in SPAC-related activity with 4/6 filings being S-4 registrations for business combinations (Exascale Labs, Puget Energy, McCarthy Finney, Electra Vehicles), alongside two S-1 filings for new SPAC IPOs and follow-ons (Yorkville International, Vivakor), signaling robust de-SPAC and blank-check company momentum on May 14, 2026. Positive sentiment dominates high-materiality deals like Yorkville's $200M IPO and Exascale's merger with 94% voting power retention, while neutral tones prevail in energy-focused filings with multi-period XBRL data (Puget FY2023-2026, Vivakor FY2024-2025). Period-over-period trends are nascent but highlight operational expansions via acquisitions (Vivakor's Endeavor Crude Oct 2024) and divestitures (Jul 2025), with no explicit revenue/margin declines noted across filings. Key implications include potential market re-entry for tech/AI (Electra at $250M valuation) and energy firms via SPACs, with dilution risks from warrants/redemptions and insider-held founder shares. Portfolio-level pattern: 67% of filings tied to SPACs, favoring emerging markets/tech over traditional IPOs, positioning investors for post-effectiveness catalysts.

6 high priority 6 total filings
· daily

Global High-Priority Regulatory Events — May 14, 2026

Across 50 filings in the Global High Priority Market Events stream (US SEC focus), dominant themes include SPAC lifecycle events (IPOs, extensions, Q1 results with interest-driven net income amid operating losses), Indian corporate actions (buybacks signaling confidence, insolvencies/distress proceedings), and mixed Q1 2026 results for operating companies with revenue declines in media/advertising offset by cash generation or M&A boosts. Period-over-period trends show 6/15 detailed 10-Qs with YoY revenue growth (e.g., Healthcare Triangle +166%, AIxCrypto liquidity via note sale), but 5 with declines (Versant -1.1%, SpringBig -1.3%) and widespread margin pressure or loss widening (Cabaletta +21% net loss); SPACs averaged +500% YoY net income from trust interest but expanding deficits. Critical developments like CSX's $5B buyback authorization, Lumen's $2.4B debt refinancing, Mangalore Refinery's ₹212cr refund win, and Onward/Cybertech buybacks highlight capital returns and deleveraging, while insolvencies (AGS Transact, Sir Shadi Lal scheme) flag distress. Portfolio-level patterns reveal SPAC resilience via extensions (GP-Act III to Nov 2026) but going concern risks (Vernal), and Indian firms splitting between bullish buybacks (avg 2.5% share capital) and negative CIRP. Implications: Tactical opportunities in buybacks/refinancings, caution on biotech/media distress, monitor SPAC combinations.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — May 14, 2026

Across 50 Q1 2026 10-Q filings, overarching themes include mixed sentiment dominated by SPACs (e.g., Inflection Point, SUMA, Sizzle) generating net income from trust interest (avg ~$1-2M per quarter) amid operating losses and cash burn, while operating companies show polarized revenue trends: 12/25 reported YoY growth (avg +70%, led by Healthcare Triangle +166%, BitGo +113%) but 13 saw declines (avg -40%, e.g., New Fortress -52%, Swarmer -82%). Margin compression affected 8/15 detailed cos (avg -150 bps) due to rising opex/R&D, though gross margins expanded in winners like Enovix (+495% gross profit). Balance sheets bolstered by financings/IPOs (e.g., Cabaletta cash +41% QoQ, Swarmer +153%), but cash burn intensified in 20+ cos (avg op cash use $1-3M). Capital allocation leans conservative with distributions up in REITs/BDCs (Blue Owl +7%, Oaktree Gardens +30% YoY), few buybacks. No widespread insider activity reported, but high materiality names (New Fortress 9/10, StubHub 9/10) signal sector rotation potential from energy/tech distress to fintech/REIT recovery. Portfolio implication: overweight revenue accelerators, avoid prolonged cash burners.

50 high priority 50 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — May 14, 2026

Across 50 8-K filings in the USA Corporate Distress & Bankruptcy stream (May 14, 2026 period), overarching themes include aggressive debt refinancing (25+ issuances/amendments totaling billions, e.g., Lumen $2.4B, IREN $3B, Constellation $2.2B) to extend maturities and repay near-term obligations, signaling proactive deleveraging amid higher rates rather than outright insolvency. Explicit distress peaks with Trinseo's $2B debt-cut RSA via pre-pack Chapter 11, Society Pass's Chapter 11 filing, and FREIT's liquidation plan (60-97% premium), representing 6% of filings but high materiality (10/10). Where period data available, trends mixed: Applied Materials +11% YoY revenue, +0.8pts gross margin to 49.9%, EPS +33% YoY contrasts HyOrc/GridAI dilutive raises; no broad insider selling/buying patterns noted. Capital allocation favors refinancings/repayments over dividends/buybacks (e.g., AEP forward sales, Tyler $1.4B notes + repurchases). Forward catalysts cluster in Q3 2026 (acquisitions, closings). Portfolio-level: moderate distress with refinancings mitigating bankruptcy risks, but REIT/energy small caps vulnerable; relative outperformance in semis/utilities.

50 high priority 50 total filings
· daily

US Executive Officer Management Changes SEC — May 14, 2026

Across 24 filings in the USA Executive & Director Changes stream (May 14, 2026), dominant themes include orderly C-suite retirements with named successors in insurance (RenaissanceRe CFO/CPO retire Dec 2026/Jan 2027, Selective CIO retires June 2026), sudden separations without detailed reasons (CSX CTO immediate exit, Ocugen CMO May 8, Xponential COO May 13), and positive board appointments in financials/biotech (AIG independent director June 1, Corbus pharma veteran ahead of ASCO). Capital allocation remains bullish with new $5B CSX share repurchase (atop $989M remaining) and $3B KeyCorp program replacing $1B prior ($280M left), signaling management confidence amid stable dividends. Annual meetings showed strong approvals but pockets of opposition (e.g., CSX director votes 299M against, Fulgent 6M withheld on director). NeoVolta outlier with 262% 9-mo revenue growth to $13.3M despite flat Q3, gross margins +20pp to 46%; no broad YoY/QoQ deterioration but diverse sectors limit portfolio trends. Implications: Succession planning enhances stability (positive for insurers), abrupt exits flag monitoring (COO/CTO roles), buybacks boost returns in transport/banks.

24 high priority 24 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — May 14, 2026

The USA Bankruptcy & Insolvency stream features a single high-materiality (10/10) Chapter 11 filing by Society Pass Incorporated (SOPA), signaling acute financial distress in the travel and media sectors. No period-over-period financial trends are detailed in the filing, but the voluntary petition implies severe liquidity constraints and operational challenges culminating in bankruptcy on May 12, 2026. Key developments include joint administration in the Southern District of Texas, operations continuing as debtors-in-possession, and a default under the Prepetition Insurance Agreement with automatic stay on enforcement. Equity trading on Nasdaq is deemed highly speculative with substantial risks, likely leading to significant shareholder value erosion. Negative sentiment dominates, with no bullish indicators from insider activity, capital allocation, or forward-looking guidance beyond first-day motions. Portfolio-level implications highlight insolvency risks for small-cap travel/media firms amid economic pressures.

1 high priority 1 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 14, 2026

The 24 filings reveal a surge in boardroom stability through annual meetings (Fulgent, CSX, Cushman, DMC Global, Delcath, InfuSystem) with director elections mostly passing despite notable opposition in Fulgent (up to 6M withheld for Groves) and CSX (299M against Zillmer). Executive transitions dominate, with orderly retirements and appointments (Selective CIO to interim, RenaissanceRe CFO/CPO to internal successors Jan 2027, AIG independent dir Jun 1, Standex CFO promo), but abrupt separations (CSX EVP immediate, Ocugen CMO May 8, Xponential COO May 13) raise flags. Capital allocation shines with CSX's $5B buyback atop $989M remaining and KeyCorp's $3B program replacing $1B ($280M left) plus $0.205 dividend; equity plans approved widely (Fulgent 2M+1.5M shares, Cushman 12M+, Delcath +1.8M). NeoVolta outlier with Q3 revenue flat YoY at $2M but 9-mo +262% to $13.3M, margins 46% vs 26% YoY despite wider $3M loss. Portfolio trends: Positive sentiments in 7/24 (e.g., insurance, fitness), mixed/neutral elsewhere; no broad insider selling but appointments signal conviction. Implications: Bullish for capital returns in financials/transport, monitor governance dissent and transitions for execution risks.

24 high priority 24 total filings
· daily

US Merger & Acquisition SEC Filings — May 14, 2026

The 16 filings reveal a surge in SPAC activity with 10 new or progressing blank check companies (IPOs, unit separations, extensions, and de-SPAC advancements), signaling robust M&A appetite amid a tight deadline environment, while 5 major acquisitions completed on May 14, 2026, across pharma (Apellis/Biogen), telecom (CSG/NEC), marine (Off The Hook/Apex), and homebuilding (Tri Pointe/Sumitomo). Period-over-period trends show SPACs like Boost Run (Willow Lane) posting net income growth to $3.4M in 2025 from $0.1M in 2024 driven by trust interest, but cash declines and widening deficits highlight liquidity strains common to 4/16 filings. Completed deals emphasize accretive synergies (Biogen EPS boost 2027, Off The Hook millions in savings), with forward-looking catalysts like CVRs up to $4/share and Phase 3 data H1 2027. Portfolio-level patterns indicate SPAC extensions averting liquidation (e.g., GP-Act III to Nov 2026), but going concern doubts in 3 SPACs and proxy risks in Mountain Lake underscore execution risks. Market implications include heightened M&A momentum in US equities, favoring acquirers like Biogen and Sumitomo for growth, while SPACs offer de-SPAC alpha if targets materialize.

16 high priority 16 total filings
· monthly

US Pre-Market SEC Filings Roundup — May 14, 2026

Across 50 overnight SEC filings, Q1 2026 results dominate with mixed sentiments: 12/25 10-Qs showed revenue growth averaging +45% YoY (e.g., Lifeway +37%, Intelligent Bio +46%, Karman +51%), but 8 reported declines averaging -35% YoY (e.g., New Fortress -52%, Swarmer -82%), highlighting sector divergence in consumer/health vs energy/tech. SPACs (10 filings) exhibit stability via trust interest income (avg +$1.5M/quarter offsetting operating losses), though cash burns and deficits persist. Debt refinancings (Lumen, Encore upsized €325M notes) and offerings signal financial maneuvers amid positive capital access, while biotech advances (Onconetix publications, Editas 90% LDL-C reduction) provide catalysts. No insider trading reported across filings, but capital allocation trends favor dividends/distributions (Blue Owl +7% payout, News Corp $1B buyback program). Portfolio-level: Margin expansions in 5 firms (Lifeway +360bps, Intelligent Bio +170bps), but compressions in others (Springbig gross -16.8%). Implications: Favor health/consumer outperformers pre-market; monitor SPAC extensions/deadlines for M&A catalysts.

33 high priority 17 medium 50 total filings
· daily

Federal Construction & Infrastructure Contracts — May 13, 2026

This digest synthesizes $1,720,040,000 in federal construction and infrastructure contracts over May 13, 2026, with a 0/1 defense-civilian split—all civilian obligations led by Department of Homeland Security. The dominant theme is DHS infrastructure investment via a single $1.72B award to SOUTHWEST VALLEY CONSTRUCTORS CO. Highest-conviction bullish signal (7/10 strength, 8/10 materiality) highlights the company's positioning in large-scale federal construction. No defense signals present, emphasizing civilian sector momentum. Key risk: unknown competition and pricing structures expose potential margin pressures or protest vulnerabilities. Watch DHS budget execution for follow-on opportunities amid construction sector growth.

1 total filings
· daily

DHS Homeland Security Contracts — May 13, 2026

DHS drove the entire $1,720,040,000 obligation in this period via a single contract award to SOUTHWEST VALLEY CONSTRUCTORS CO on May 11, 2026. This represents a 100% civilian split (0/1 defense-related), with DHS as the dominant agency focusing on homeland security construction. The highest-conviction signal is bullish on SOUTHWEST VALLEY CONSTRUCTORS CO, rated 7/10 strength and 8/10 materiality, indicating potential growth in civilian infrastructure. One key risk is the unknown competition signal, which could expose the award to protests. Watch for details on pricing structure and contract vehicle to gauge durability amid DHS budget priorities.

1 total filings
· daily

VA Healthcare & Services Contracts — May 13, 2026

The Department of Veterans Affairs awarded Booz Allen Hamilton Inc. a single $809,754,946 delivery order for IT operations and services transformation, representing 100% civilian exposure with 0/1 defense-related contracts. This fully committed time-and-materials contract under full and open competition provides high funding certainty through 2025-01-22, with $317,898,571 already outlayed and steady annual revenue estimated at $140-145 million. The dominant agency theme is VA healthcare IT services modernization via NAICS 541512 and PSC D318. Highest-conviction bullish signal is Booz Allen's stable multi-year VA revenue stream amid low pricing risk. Key watch item: progress on remaining ~$492 million outlays and any modifications to the 2025-01-22 end date amid uncertain pacing.

1 total filings
· daily

HHS & Healthcare Contracts Intelligence — May 13, 2026

HHS awarded $1,574,385,405 in healthcare contracts from May 13, 2026, all civilian with zero defense-related activity, dominated by BARDA/ASPR funding for viral vaccine R&D and manufacturing. The highest-conviction bullish signal is Bavarian Nordic A/S's $1,264,240,981 award, representing 80% of total obligations and signaling strong demand in biotech preparedness. Albert B. Sabin Vaccine Institute, Inc. captured the remaining $310,144,424 across two neutral contracts for Sudan Ebolavirus and Marburg/Sudan vaccines, but its nonprofit status eliminates direct equity upside. Key watch item: option exercises on Sabin contracts toward $240M and $149.7M ceilings, with $62M and $88M already outlayed.

3 total filings
· daily

New Federal Contractors — May 13, 2026

This digest covers 6 new federal contractor awards totaling $4,176,750,195 in obligations, all civilian agency contracts (0/6 defense-related) from May 13, 2026. Dominant themes include massive construction and health-related commitments from DHS ($1.72B to Southwest Valley Constructors) and HHS ($1.26B to Bavarian Nordic A/S plus $310M across two to Albert B. Sabin Vaccine Institute), alongside VA IT services ($810M to Booz Allen Hamilton). Highest-conviction bullish signals stem from the top three high-materiality awards ($1.72B, $1.26B, $810M), signaling multi-year revenue stability for recipients despite limited defense exposure. Key risk is uneven outlay pacing, with Booz Allen at 39% ($318M of $810M), Sabin contracts at ~38-60%, and Nelson at 15% ($10.7M of $72.6M), warranting monitoring for funding continuity amid CR uncertainty.

6 total filings
· daily

Significant Contract Modifications ($10M+) — May 13, 2026

This digest synthesizes $4,176,750,195 in significant civilian contract modifications (0/6 defense-related) across DHS, HHS, VA, and USAID for the period May 13-13, 2026. Dominant agency themes include massive HHS commitments to vaccine developers ($1.26B to BAVARIAN NORDIC A/S and $310M across two awards to ALBERT B. SABIN VACCINE INSTITUTE, INC.) and large VA/DHS IT/construction plays ($810M Booz Allen Hamilton VA IT services; $1.72B Southwest Valley Constructors DHS). Highest-conviction bullish signal is Booz Allen Hamilton's $809.8M VA time-and-materials IT delivery order with $317.9M already outlayed and low pricing risk over 5+ years. Key risk/watch item: outlay pacing on long-term contracts (e.g., Sabin's HHS awards with $150.7M outlayed vs. $310M obligated; Nelson's $72.6M USAID with only $10.7M outlayed).

6 total filings
· daily

Contract Deobligations Alert — May 13, 2026

This Contract Deobligations Alert synthesizes $4,176,750,195 in total civilian contract obligations across 6 awards from May 13, 2026, with 0/6 defense-related and average signal strength of 5.5/10, dominated by DHS ($1.72B), HHS ($1.57B across Bavarian Nordic A/S and Albert B. Sabin Vaccine Institute), and VA ($810M). Highest-conviction bullish signals (7/10 strength, 8/10 materiality) highlight durable revenue potential for Southwest Valley Constructors Co ($1.72B DHS), Bavarian Nordic A/S ($1.26B HHS), and Booz Allen Hamilton Inc ($809.8M VA IT services). Neutral signals temper smaller HHS R&D awards to Albert B. Sabin Vaccine Institute ($310M total) and USAID remediation to Nelson Environmental Remediation USA Ltd ($72.6M). Key risk: monitor outlay progress on multi-year contracts like Booz Allen's remaining $492M unoutlayed on VA order and Nelson's high firm-fixed-price execution risk.

6 total filings
· daily

Contract Option Exercises — May 13, 2026

Option exercises totaling $4,176,750,195 across 6 civilian contracts (0/6 defense-related) highlight steady funding commitments from HHS ($1.57B in vaccine R&D), DHS ($1.72B construction), VA ($810M IT services), and USAID ($73M remediation), with average signal strength of 5.5/10. Dominant theme is civilian health preparedness via HHS awards to BAVARIAN NORDIC A/S ($1.26B) and ALBERT B. SABIN VACCINE INSTITUTE ($310M across two contracts), alongside large VA IT support for BOOZ ALLEN HAMILTON INC. Highest-conviction bullish signal is BOOZ ALLEN HAMILTON's $809.8M VA delivery order with $317.9M already outlayed under low-risk time-and-materials pricing through 2025. Key risk is uneven outlay pacing in multi-year contracts, such as BOOZ ALLEN's remaining $492M and NELSON ENVIRONMENTAL REMEDIATION USA LTD's early 15% ($10.7M) on $72.6M USAID award.

6 total filings